Fortescue (ASX: FMG) Share Price Is Climbing Again as Iron Ore Momentum Returns to the ASX
Fortescue (ASX: FMG) shares have rebounded on stronger iron ore prices, improving Chinese demand and solid shipments. Sentiment is also lifted by dividends and production strength, while its green energy transition and decarbonisation plans support long-term growth above A$20 momentum.
Can Cleanaway (ASX: CWY) Re Rate Higher as Margins Expand and Strategy 2030 Takes Hold?
Cleanaway (ASX: CWY) is rebuilding momentum through upgraded EBIT guidance, margin expansion, and a stronger strategic framework, with valuation support emerging as earnings and free cash flow accelerate.
Netwealth Group (ASX: NWL): $101M Paid Out, Yet First Guardian Fight Rolls On
Netwealth (ASX: NWL) confirms it will fight a class action over First Guardian investment options on its super platform, as shares slide following the formal Statement of Claim.
Viva Energy Group (ASX: VEA): Strong Half, But How Sustainable Are Earnings?
Viva Energy delivered a strong 1H26, with EBITDA and free cash flow surging on exceptional refining margins. However, earnings remain exposed to refinery cyclicality and operational risks, making normalised EPS of A$0.20–A$0.25 more appropriate for sustainable valuation.
Accent Group (ASX: AX1) — A Scaled Retailer Mispriced for What It Can Deliver
We continue to view Accent Group (AX1) as one of the few genuinely scaled, defensible retail platforms in Australia and New Zealand. In a sector where earnings volatility is the norm and brand power often trumps execution, AX1 stands out because it has quietly built a multi-brand ecosystem that gives it pricing control, data-driven consumer reach, and operational leverage that smaller retailers simply cannot replicate.
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.